Literature DB >> 21511186

A subset of interleukin-21+ chemokine receptor CCR9+ T helper cells target accessory organs of the digestive system in autoimmunity.

Helen M McGuire1, Alexis Vogelzang, Cindy S Ma, William E Hughes, Pablo A Silveira, Stuart G Tangye, Daniel Christ, David Fulcher, Marika Falcone, Cecile King.   

Abstract

This study describes a CD4+ T helper (Th) cell subset marked by coexpression of the cytokine interleukin 21 (IL-21) and the gut-homing chemokine receptor CCR9. Although CCR9+ Th cells were observed in healthy mice and humans, they were enriched in the inflamed pancreas and salivary glands of NOD mice and in the circulation of Sjögren's syndrome patients. CCR9+ Th cells expressed large amounts of IL-21, inducible T cell costimulator (ICOS), and the transcription factors Bcl6 and Maf, and also supported antibody production from B cells, thereby resembling T follicular B helper (Tfh) cells. However, in contrast to Tfh cells, CCR9+ Th cells displayed limited expression of CXCR5 and the targets of CCR9+ Th cells were CD8+ T cells whose responsiveness to IL-21 was necessary for the development of diabetes. Thus, CCR9+ Th cells are a subset of IL-21-producing T helper cells that influence regional specification of autoimmune diseases that affect accessory organs of the digestive system.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21511186     DOI: 10.1016/j.immuni.2011.01.021

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  53 in total

1.  IL-21 promotes lupus-like disease in chronic graft-versus-host disease through both CD4 T cell- and B cell-intrinsic mechanisms.

Authors:  Vinh Nguyen; Irina Luzina; Horea Rus; Cosmin Tegla; Ching Chen; Violeta Rus
Journal:  J Immunol       Date:  2012-06-20       Impact factor: 5.422

2.  Cell-intrinsic IL-27 and gp130 cytokine receptor signaling regulates virus-specific CD4⁺ T cell responses and viral control during chronic infection.

Authors:  James A Harker; Aleksandr Dolgoter; Elina I Zuniga
Journal:  Immunity       Date:  2013-08-29       Impact factor: 31.745

Review 3.  Interleukin-21: a double-edged sword with therapeutic potential.

Authors:  Rosanne Spolski; Warren J Leonard
Journal:  Nat Rev Drug Discov       Date:  2014-04-22       Impact factor: 84.694

4.  A pathogenetic role for IL-21 in primary Sjögren syndrome.

Authors:  Seung-Ki Kwok; Jennifer Lee; Di Yu; Kwi Young Kang; Mi-La Cho; Hae-Rim Kim; Ji Hyeon Ju; Sang-Heon Lee; Sung-Hwan Park; Ho-Youn Kim
Journal:  Nat Rev Rheumatol       Date:  2015-01-13       Impact factor: 20.543

5.  Local triggering of the ICOS coreceptor by CD11c(+) myeloid cells drives organ inflammation in lupus.

Authors:  Lino L Teichmann; Jaime L Cullen; Michael Kashgarian; Chen Dong; Joe Craft; Mark J Shlomchik
Journal:  Immunity       Date:  2015-03-17       Impact factor: 31.745

6.  SUMO-defective c-Maf preferentially transactivates Il21 to exacerbate autoimmune diabetes.

Authors:  Chao-Yuan Hsu; Li-Tzu Yeh; Shin-Huei Fu; Ming-Wei Chien; Yu-Wen Liu; Shi-Chuen Miaw; Deh-Ming Chang; Huey-Kang Sytwu
Journal:  J Clin Invest       Date:  2018-07-30       Impact factor: 14.808

7.  Interleukin-15 plays an essential role in the pathogenesis of autoimmune diabetes in the NOD mouse.

Authors:  D Bobbala; X-L Chen; C Leblanc; M Mayhue; J Stankova; T Tanaka; Y-G Chen; S Ilangumaran; S Ramanathan
Journal:  Diabetologia       Date:  2012-08-14       Impact factor: 10.122

Review 8.  The important role of T cells and receptor expression in Sjögren's syndrome.

Authors:  A Karabiyik; A B Peck; C Q Nguyen
Journal:  Scand J Immunol       Date:  2013-08       Impact factor: 3.487

Review 9.  Mechanistic basis of immunotherapies for type 1 diabetes mellitus.

Authors:  Wenhao Chen; Aini Xie; Lawrence Chan
Journal:  Transl Res       Date:  2013-01-22       Impact factor: 7.012

10.  Induction of autoimmune diabetes in non-obese diabetic mice requires interleukin-21-dependent activation of autoreactive CD8⁺ T cells.

Authors:  X-L Chen; D Bobbala; G M Rodriguez; M Mayhue; Y-G Chen; S Ilangumaran; S Ramanathan
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.